<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04686656</url>
  </required_header>
  <id_info>
    <org_study_id>tayfun1</org_study_id>
    <nct_id>NCT04686656</nct_id>
  </id_info>
  <brief_title>Nasal Versus Buccal Oxygen Administration for Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration</brief_title>
  <official_title>A Randomized Controlled Trial Comparing Nasal With Buccal Oxygen Administration for Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antalya Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Antalya Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare to nasal and buccal oxygen administration in patients&#xD;
      undergoing Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anesthesia for Endobronchial Ultrasound (EBUS) may be range from routine bronchoscopy&#xD;
      sedation to general anesthesia. During sedation to EBUS increased duration of anesthesia and&#xD;
      sedative dosing put patients at increased risk for hypoxic events. To avoid this, oxygen&#xD;
      supplementation is mandatory. There are different techniques for oxygen supplementation&#xD;
      during the procedure. At this study we will compare to nasal and buccal oxygen&#xD;
      supplementations during EBUS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 24, 2020</start_date>
  <completion_date type="Actual">April 6, 2021</completion_date>
  <primary_completion_date type="Actual">February 24, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hypoxia-related interruptions</measure>
    <time_frame>30 minutes</time_frame>
    <description>the number of hypoxia-related interruptions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>duration of procedure</measure>
    <time_frame>30 minutes</time_frame>
    <description>Duration of procedure will be defined in minute as the time from starting to insert EBUS device until the time to remove the device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>use of propofol</measure>
    <time_frame>30 minutes</time_frame>
    <description>The use of amount of propofol will be noted during the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>use of fentanyl</measure>
    <time_frame>30 minutes</time_frame>
    <description>The use of amount of fentanyl will be noted during the procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>satisfaction of pulmonary specialist</measure>
    <time_frame>30 minutes</time_frame>
    <description>satisfaction of pulmonary specialist will be evaluated by 4-points Likert Scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Lung Diseases</condition>
  <arm_group>
    <arm_group_label>nasal oxygen supplementation group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>supplemental oxygen will be administered with nasal cannula</description>
  </arm_group>
  <arm_group>
    <arm_group_label>buccal oxygen supplementation group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>supplemental oxygen will be administered with Ring-Adair-Elwyn (RAE) tube</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>nasal oxygen</intervention_name>
    <description>Nasal cannula will be placed by the anesthesiologist. 6 l/ min of supplemental oxygen will be administered with nasal cannula.</description>
    <arm_group_label>nasal oxygen supplementation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>buccal oxygen</intervention_name>
    <description>Ring-adair-elwyn (RAE) tube will be placed by the anesthesiologist. 6 l/ min of supplemental oxygen will be administered with RAE tube.</description>
    <arm_group_label>buccal oxygen supplementation group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients â‰¥18 years of age&#xD;
&#xD;
          -  body mass index (BMI) between 20 and 30&#xD;
&#xD;
          -  American Society of Anesthesiologists physical status I-III&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  congestive heart failure&#xD;
&#xD;
          -  ischemic heart disease&#xD;
&#xD;
          -  increased intracranial pressure&#xD;
&#xD;
          -  known allergy or contraindication to study drugs (propofol, fentanyl, or midazolam)&#xD;
&#xD;
          -  an anatomical feature precluding adequate positioning of the buccal device.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>tayfun sugur, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antalya Training and Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Antalya Training and Researching Hospital</name>
      <address>
        <city>Antalya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

